⚡ StockFin Pro Unlimited AI queries. No ads. Full research access. View Plans → Ad

Shilpa Medicare Limited (SHILPAMED) — Announcement

· NSE Neutral

Shilpa Medicare Limited disclosed that the USFDA conducted a Pre-Approval Inspection at its Bengaluru Unit VI facility from May 25-29, 2026, issuing Form 483 with five procedural observations. The company confirmed it will address all observations within the stipulated timeline and does not anticipate any material impact on operations or supply chains. The facility maintains strong regulatory credentials, including EMA, MHRA, TGA, and Saudi FDA accreditations alongside its USFDA approval. This intimation complies with SEBI Listing Obligations and Disclosure Requirements under Regulation 30.

📄 View Original Announcement (PDF)

⚡ StockFin Pro Unlimited AI queries. No ads. Full research access. View Plans → Ad
📊 Stock Analysis — SHILPAMED ✨ Ask AI About This

About Shilpa Medicare Limited (SHILPAMED)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹9,356.63 Cr P/E: 106.1

View full SHILPAMED stock details →

📡 Get AI alerts when SHILPAMED files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track SHILPAMED — Free

💡 Ask AI about this filing

Ask AI Free →

📊 More SHILPAMED filings

See all SHILPAMED filings →

🔥 Also filed on 30 May 2026

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

📡 Get AI alerts when SHILPAMED files new disclosures

Track SHILPAMED filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track SHILPAMED — Free

Free account · 2 AI queries/day

⚡ StockFin Pro Go Pro — Unlimited queries, no ads Upgrade Ad

© 2026 StockFin.ai — AI-powered Indian stock research

Today's Announcements · Screener · Insights · AI Chat